Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

被引：17

作者：

Dumas, Pierre-Yves ^{[1
]}

Raffoux, Emmanuel ^{[2
]}

Berard, Emilie ^{[3
]}

Bertoli, Sarah ^{[4
]}

Hospital, Marie-Anne ^{[5
]}

Heiblig, Mael ^{[6
]}

Desbrosses, Yohann ^{[7
]}

Bonmati, Caroline ^{[8
]}

Pautas, Cecile ^{[9
]}

Lambert, Juliette ^{[10
]}

Orvain, Corentin ^{[11
,12
]}

Banos, Anne ^{[13
]}

Pasquier, Florence ^{[14
]}

Peterlin, Pierre ^{[15
]}

Marchand, Tony ^{[16
]}

Uzunov, Madalina ^{[17
]}

Frayfer, Jamile ^{[18
]}

Turlure, Pascal ^{[19
]}

Cluzeau, Thomas ^{[20
]}

Jourdan, Eric ^{[21
]}

Himberlin, Chantal ^{[22
]}

Tavernier, Emmanuelle ^{[23
]}

Villate, Alban ^{[24
]}

Haiat, Stephanie ^{[25
]}

Chretien, Marie-Lorraine ^{[26
]}

Carre, Martin ^{[27
]}

Chantepie, Sylvain ^{[28
]}

Vaida, Ioana ^{[29
]}

Wemeau, Mathieu ^{[30
]}

Chebrek, Safia ^{[31
]}

Guillerm, Gaelle ^{[32
]}

Guieze, Romain ^{[33
,34
]}

Debarri, Houria ^{[35
]}

Gehlkopf, Eve ^{[36
]}

Laribi, Kamel ^{[37
]}

Marcais, Ambroise ^{[38
]}

Santagostino, Alberto ^{[39
]}

Bene, Marie-Christine ^{[40
]}

Mineur, Ariane ^{[1
]}

Pigneux, Arnaud ^{[1
]}

Dombret, Herve ^{[2
]}

Recher, Christian ^{[4
]}

机构：

[1] CHU Bordeaux, Serv Hematol Clin & Therapie Cellulaire, F-33000 Bordeaux, France

[2] Hop St Louis, AP HP, Serv Hematol Adultes, Paris, France

[3] Univ Toulouse III Paul Sabatier, Ctr Hosp Univ Toulouse, Serv Epidemiol, INSERM,CERPOP, Toulouse, France

[4] Univ Toulouse III Paul Sabatier, Ctr Hosp Univ Toulouse, Inst Univ Canc Toulouse Oncopole, Toulouse, France

[5] Inst Paoli Calmettes, Marseille, France

[6] Hosp Civils Lyon, Serv Hematol Clin, Hop Lyon Sud, Pierre Benite, France

[7] CHRU Jean Minjoz, Serv Hematol, F-25000 Besancon, France

[8] CHU Nancy Brabois, Serv Hematol, F-54500 Vandoeuvre Les Nancy, France

[9] CHU Henri Mondor, Serv Hematol Clin & Therapie Cellulaire, 1 Rue Gustave Eiffel, F-94010 Creteil, France

[10] Ctr Hosp Versailles, Serv Hematol, Le Chesnay, France

[11] CHU Angers, Serv Malad Sang, F-49000 Angers, France

[12] Nantes Univ, CRCI2NA, CNRS UMR 6075,Univ Angers, Inserm UMR 1307,Federat Hosp Univ Grand Ouest Leu, F-49000 Angers, France

[13] Ctr Hosp Cote Basque, Serv Hematol, F-64100 Bayonne, France

[14] Univ Paris Saclay, Dept Hematol, Gustave Roussy, Villejuif, France

[15] Nantes Univ Hosp, Hematol Dept, Nantes, France

[16] CHU Rennes, Serv Hematol Clin, F-35000 Rennes, France

[17] Hop La Pitie Salpetriere, Serv Hematol, Paris, France

[18] Hop Meaux, Serv Hematol, Meaux, France

[19] CHU Limoges, Serv Hematol Clin & Therapie Cellulaire, F-87000 Limoges, France

[20] Univ Cote Azur, Dept Hematol Clin, CHU Nice, Nice, France

[21] Nimes Univ Hosp, Dept Hematol, Nimes, France

[22] Ctr Hosp Univ Reims, Hop Robert Debre, Reims, France

[23] CHU St Etienne, Serv Hematol Clin & Therapie Cellulaire, F-42000 St Etienne, France

[24] CHRU Tours, Hematol & Therapie Cellulaire, Tours, France

[25] Ctr Hosp Sud Francilien, Serv Hematol Clin, Corbeil Essonnes, France

[26] CHU Dijon, Serv Hematol Clin, Dijon, France

[27] CHU Grenoble Alpes, Grenoble, France

[28] CHU Caen, IHBN, Serv Hematol Clin, Caen, France

[29] Ctr Hosp Rene Dubos, Serv Hematol & Therapie Cellulaire, Cergy Pontoise, France

[30] CH Roubaix, Serv Hematol, F-59100 Roubaix, France

[31] CH Avignon, Serv Oncohematol, Avignon, France

[32] CHU Brest, Hop Morvan, Serv Cancerol Hematol, Brest, France

[33] CHU Clermont Ferrand, Serv Hematol Clin & Therapie Cellulaire, Clermont Ferrand, France

[34] Univ Clermont Auvergne, EA 7453 CHELTER, Clermont Ferrand, France

[35] CHR Metz Thionville, Hop Mercy, Serv Hematol, Metz, France

[36] CHU Montpellier, Hop St Eloi, Serv Hematol Clin, F-34295 Montpellier, France

[37] Ctr Hosp Le Mans, Dept Haematol, Le Mans, France

[38] Univ Paris Cite, Hop Necker Enfants Malad, Assistance Publ Hop Paris, Serv Hematol Adultes, Paris, France

[39] CHT Troyes, Serv Hematol Clin, F-10000 Troyes, France

[40] Nantes Univ Hosp, Hematol Biol, Nantes, France

来源：

LEUKEMIA | 2023年 / 37卷 / 01期

关键词：

FLT3; MUTATIONS; CYTOGENETICS; DIAGNOSIS;

D O I：

10.1038/s41375-022-01742-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B), including 67 previously treated by intensive chemotherapy and midostaurin (cohort C). The main differences in patient characteristics in this study compared to the ADMIRAL trial were ECOG >= 2 (83.6% vs. 16.6%), FLT3-TKD mutation (21.0% vs. 8.5%), primary induction failure (15.0% vs. 40.0%) and line of treatment (beyond 2nd in 37.1% vs. 0.0%). The rates of composite complete remission, excluding those that occurred after hematopoietic stem cell transplantation (HSCT), were similar at respectively 25.4% and 27.5% in cohorts B and C. Median overall survival (OS) for these two groups was also similar at respectively 6.4 and 7.8 months. Multivariate analyses for prognostic factors associated with OS identified female gender (HR 1.61), adverse cytogenetic risk (HR 2.52), and allogenic HSCT after gilteritinib (HR 0.13). Although these patients were more heavily pretreated, these real-world data reproduce the results of ADMIRAL and provide new insights into the course of patients previously treated by intensive chemotherapy and midostaurin and beyond the 2nd line of treatment who can benefit from treatment in an outpatient setting.

引用

页码：91 / 101

页数：11

共 50 条

[31] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy
Ong, Faustine
Short, Nicholas
Daver, Naval
Kadia, Tapan M.
DiNardo, Courtney D.
Yilmaz, Musa
Alvarado, Yesid
Vaughan, Kenneth
Pierce, Sherry A.
Kantarjian, Hagop
Garcia-Manero, Guillermo
Ravandi, Farhad
BLOOD, 2022, 140 : 9029 - 9031
[32] Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory AML: phase 3 ADMIRAL trial results
Perl, Alexander E.
Martinelli, Giovanni
Cortes, Jorge E.
Neubauer, Andreas
Berman, Ellin
Paolini, Stefania
Montesinos, Pau
Baer, Maria R.
Larson, Richard A.
Ustun, Celalettin
Fabbiano, Francesco
Di Stasi, Antonio
Stuart, Robert
Olin, Rebecca
Kasner, Margaret
Ciceri, Fabio
Chou, Wen-Chien
Podoltsev, Nikolai
Recher, Christian
Yokoyama, Hisayuki
Hosono, Naoko
Yoon, Sung-Soo
Lee, Je-Hwan
Pardee, Timothy
Fathi, Amir T.
Liu, Chaofeng
Liu, Xuan
Bahceci, Erkut
Levis, Mark J.
SWISS MEDICAL WEEKLY, 2019, 149 : 3S - 4S
[33] Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors
Numan, Yazan
Rahman, Zaid Abdel
Grenet, Justin
Boisclair, Stephanie
Bewersdorf, Jan Philipp
Barth, Dylan
Zeidan, Amer M.
Yilmaz, Musa
Dinner, Shira
Deutsch, Yehuda E.
Frankfurt, Olga
Litzow, Mark
Al-Kali, Aref
Foran, James M.
Sproat, Lisa Z.
Jovanovic, Borko
Daver, Naval
Perl, Alexander E.
Altman, Jessica K.
BLOOD, 2020, 136
[34] Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
Ma, Jun
Zhao, Shoujing
Qiao, Xinan
Knight, Tristan
Edwards, Holly
Polin, Lisa
Kushner, Juiwanna
Dzinic, Sijana H.
White, Kathryn
Wang, Guan
Zhao, Lijing
Lin, Hai
Wang, Yue
Taub, Jeffrey W.
Ge, Yubin
CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6815 - 6826
[35] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
Perl, Alexander E.
Martinelli, Giovanni
Cortes, Jorge E.
Neubauer, Andreas
Berman, Ellin
Paolini, Stefania
Montesinos, Pau
Baer, Maria R.
Larson, Richard A.
Ustun, Celalettin
Fabbiano, Francesco
Di Stasi, Antonio
Stuart, Robert
Olin, Rebecca
Kasner, Margaret
Ciceri, Fabio
Chou, Wen-Chien
Podoltsev, Nikolai
Recher, Christian
Yokoyama, Hisayuki
Hosono, Naoko
Yoon, Sung-Soo
Lee, Je-Hwan
Pardee, Timothy
Fathi, Amir T.
Liu, Chaofeng
Liu, Xuan
Bahceci, Erkut
Levis, Mark J.
CANCER RESEARCH, 2019, 79 (13)
[36] Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
Smith, Catherine C.
Levis, Mark J.
Perl, Alexander E.
Martinelli, Giovanni
Neubauer, Andreas
Berman, Ellin
Montesinos, Pau
Baer, Maria R.
Larson, Richard A.
Chou, Wen-Chien
Yokoyama, Hisayuki
Recher, Christian
Yoon, Sung-Soo
Hill, Jason E.
Rosales, Matt
Bahceci, Erkut
BLOOD, 2019, 134
[37] A SYSTEMATIC REVIEW OF THE HUMANISTIC BURDEN OF FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Casamayor, M.
Gubbels, L.
Garnham, A.
Shah, M., V
VALUE IN HEALTH, 2020, 23 : S29 - S29
[38] ESTIMATION OF HEALTH STATE UTILITIES IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Cella, D.
Qi, C. Z.
Yang, H.
Garnham, A.
Shah, M., V
VALUE IN HEALTH, 2020, 23 : S77 - S78
[39] Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia
Wang, Jianxiang
Jiang, Bin
Li, Jian
Liu, Ligen
Du, Xin
Jiang, Hao
Hu, Jianda
Yuan, Menghe
Sakatani, Taishi
Kadokura, Takeshi
Takeuchi, Masato
Izuka, Shunsuke
Girshova, Larisa
Tan, Jerome
Bondarenko, Sergey N.
Wong, Lily L. L.
Khuhapinant, Archrob
Martynova, Elena
Hasabou, Nahla
Tiu, Ramon V.
BLOOD, 2021, 138
[40] Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
Gallogly, Molly M.
Lazarus, Hillard M.
Cooper, Brenda W.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (09) : 245 - 261

← 1 2 3 4 5 →